Submitted:
25 February 2024
Posted:
26 February 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. “Alkalization therapy” for cancer
2.1. Concept of alkalization therapy
2.2. Alkalization therapy; Our clinical experience to date
3. Natural products for the treatment of cancer
3.1. Triterpenoids
3.2. Parthenolide
3.3. Fulvic acid
3.4. Taxus yunnanensis (Taxus plant)
3.5. Apple pectin
4. Hypothesis: Can the combination of “alkalization therapy” and natural products have a positive effect on cancer patients?
5. Long-term survival of patients with advanced cancer treated with alkalization therapy and natural products
5.1. Study outline
5.2. Patient characteristics
5.3. Outcomes of patients treated with alkalization therapy and natural products in combination with standard treatments
6. Summary and limitations
7. Conclusion
Author Contributions
Funding
Institutional Review Board statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Siegel, R. L.; Miller, K. D.; Wagle, N. S.; Jemal, A. Cancer statistics, 2023. CA Cancer J Clin 2023, 73, 17–48. [Google Scholar] [CrossRef]
- Holohan, C.; Van Schaeybroeck, S.; Longley, D. B.; Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013, 13, 714–726. [Google Scholar] [CrossRef]
- Corbet, C.; Feron, O. Tumour acidosis: from the passenger to the driver’s seat. Nat Rev Cancer 2017, 17, 577–593. [Google Scholar] [CrossRef]
- Koppenol, W. H.; Bounds, P. L.; Dang, C. V. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer 2011, 11, 325–337. [Google Scholar] [CrossRef]
- Hamaguchi, R.; Narui, R.; Morikawa, H.; Wada, H. Improved chemotherapy outcomes of patients with small-cell lung cancer treated with combined alkalization therapy and intravenous vitamin C. Cancer Diagn Progn 2021, 1, 157–163. [Google Scholar] [CrossRef]
- Hamaguchi, R.; Ito, T.; Narui, R.; Morikawa, H.; Uemoto, S.; Wada, H. Effects of alkalization therapy on chemotherapy outcomes in advanced pancreatic cancer: A retrospective case-control study. In Vivo 2020, 34, 2623–2629. [Google Scholar] [CrossRef] [PubMed]
- Wada, H.; Hamaguchi, R.; Narui, R.; Morikawa, H. Meaning and significance of "alkalization therapy for cancer". Front Oncol 2022, 12, 920843. [Google Scholar] [CrossRef] [PubMed]
- Isowa, M.; Hamaguchi, R.; Narui, R.; Morikawa, H.; Wada, H. Effects of alkalization therapy on hepatocellular carcinoma: a retrospective study. Front Oncol 2023, 13, 1179049. [Google Scholar] [CrossRef] [PubMed]
- Block, K. I.; Koch, A. C.; Mead, M. N.; Tothy, P. K.; Newman, R. A.; Gyllenhaal, C. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int J Cancer 2008, 123, 1227–1239. [Google Scholar] [CrossRef] [PubMed]
- Farzaei, M. H.; Bahramsoltani, R.; Rahimi, R. Phytochemicals as adjunctive with conventional anticancer therapies. Curr Pharm Des 2016, 22, 4201–4218. [Google Scholar] [CrossRef] [PubMed]
- Vaupel, P.; Multhoff, G. Revisiting the Warburg effect: historical dogma versus current understanding. J Physiol 2021, 599, 1745–1757. [Google Scholar] [CrossRef] [PubMed]
- Thews, O.; Riemann, A. Tumor pH and metastasis: a malignant process beyond hypoxia. Cancer Metastasis Rev 2019, 38, 113–129. [Google Scholar] [CrossRef] [PubMed]
- Asgharzadeh, M. R.; Barar, J.; Pourseif, M. M.; Eskandani, M.; Jafari Niya, M.; Mashayekhi, M. R.; Omidi, Y. Molecular machineries of pH dysregulation in tumor microenvironment: potential targets for cancer therapy. Bioimpacts 2017, 7, 115–133. [Google Scholar] [CrossRef] [PubMed]
- Parks, S. K.; Chiche, J.; Pouyssegur, J. pH control mechanisms of tumor survival and growth. J Cell Physiol 2011, 226, 299–308. [Google Scholar] [CrossRef]
- Hirschhaeuser, F.; Sattler, U. G.; Mueller-Klieser, W. Lactate: a metabolic key player in cancer. Cancer Res 2011, 71, 6921–6925. [Google Scholar] [CrossRef] [PubMed]
- Pötzl, J.; Roser, D.; Bankel, L.; Hömberg, N.; Geishauser, A.; Brenner, C. D.; Weigand, M.; Röcken, M.; Mocikat, R. Reversal of tumor acidosis by systemic buffering reactivates NK cells to express IFN-γ and induces NK cell-dependent lymphoma control without other immunotherapies. Int J Cancer 2017, 140, 2125–2133. [Google Scholar] [CrossRef]
- Robey, I. F.; Nesbit, L. A. Investigating mechanisms of alkalinization for reducing primary breast tumor invasion. Biomed Res Int 2013, 2013, 485196. [Google Scholar] [CrossRef]
- Robey, I. F.; Baggett, B. K.; Kirkpatrick, N. D.; Roe, D. J.; Dosescu, J.; Sloane, B. F.; Hashim, A. I.; Morse, D. L.; Raghunand, N.; Gatenby, R. A.; et al. Bicarbonate increases tumor pH and inhibits spontaneous metastases. Cancer Res 2009, 69, 2260–2268. [Google Scholar] [CrossRef]
- Azzarito, T.; Lugini, L.; Spugnini, E. P.; Canese, R.; Gugliotta, A.; Fidanza, S.; Fais, S. Effect of Modified alkaline supplementation on syngenic melanoma growth in CB57/BL Mice. PLoS One 2016, 11, e0159763. [Google Scholar] [CrossRef]
- Spugnini, E. P.; Buglioni, S.; Carocci, F.; Francesco, M.; Vincenzi, B.; Fanciulli, M.; Fais, S. High dose lansoprazole combined with metronomic chemotherapy: a phase I/II study in companion animals with spontaneously occurring tumors. J Transl Med 2014, 12, 225. [Google Scholar] [CrossRef]
- Gillies, R. J.; Ibrahim-Hashim, A.; Ordway, B.; Gatenby, R. A. Back to basic: Trials and tribulations of alkalizing agents in cancer. Front Oncol 2022, 12, 981718. [Google Scholar] [CrossRef]
- Ando, H.; Eshima, K.; Ishida, T. Neutralization of acidic tumor microenvironment (TME) with daily oral dosing of sodium potassium citrate (K/Na citrate) increases therapeutic effect of anti-cancer agent in pancreatic cancer xenograft mice model. Biol Pharm Bull 2021, 44, 266–270. [Google Scholar] [CrossRef]
- Ribeiro, M. D.; Silva, A. S.; Bailey, K. M.; Kumar, N. B.; Sellers, T. A.; Gatenby, R. A.; Ibrahim-Hashim, A.; Gillies, R. J. Buffer therapy for cancer. J Nutr Food Sci 2012, 2, 6. [Google Scholar] [CrossRef]
- Robey, I. F. Examining the relationship between diet-induced acidosis and cancer. Nutr Metab (Lond) 2012, 9, 72. [Google Scholar] [CrossRef]
- Park, Y. M.; Steck, S. E.; Fung, T. T.; Merchant, A. T.; Elizabeth Hodgson, M.; Keller, J. A.; Sandler, D. P. Higher diet-dependent acid load is associated with risk of breast cancer: Findings from the sister study. Int J Cancer 2019, 144, 1834–1843. [Google Scholar] [CrossRef]
- Hoang, B. X.; Le, B. T.; Tran, H. D.; Hoang, C.; Tran, H. Q.; Tran, D. M.; Pham, C. Q.; Pham, T. D.; Ha, T. V.; Bui, N. T.; et al. Dimethyl sulfoxide-sodium bicarbonate infusion for palliative care and pain relief in patients with metastatic prostate cancer. J Pain Palliat Care Pharmacother 2011, 25, 350–355. [Google Scholar] [CrossRef]
- Hoang, B. X.; Tran, D. M.; Tran, H. Q.; Nguyen, P. T.; Pham, T. D.; Dang, H. V.; Ha, T. V.; Tran, H. D.; Hoang, C.; Luong, K. N.; et al. Dimethyl sulfoxide and sodium bicarbonate in the treatment of refractory cancer pain. J Pain Palliat Care Pharmacother 2011, 25, 19–24. [Google Scholar] [CrossRef] [PubMed]
- Martin, N. K.; Robey, I. F.; Gaffney, E. A.; Gillies, R. J.; Gatenby, R. A.; Maini, P. K. Predicting the safety and efficacy of buffer therapy to raise tumour pHe: an integrative modelling study. Br J Cancer 2012, 106, 1280–1287. [Google Scholar] [CrossRef] [PubMed]
- Robey, I. F.; Lopez, A. M.; Roe, D. J. Safety and tolerability of long-term sodium bicarbonate consumption in cancer care. Journal of Integrative Oncology 2015, 4, 128. [Google Scholar] [CrossRef]
- Liu, J. Pharmacology of oleanolic acid and ursolic acid. J Ethnopharmacol 1995, 49, 57–68. [Google Scholar] [CrossRef] [PubMed]
- Woźniak, Ł.; Skąpska, S.; Marszałek, K. Ursolic acid--A pentacyclic triterpenoid with a wide spectrum of pharmacological activities. Molecules 2015, 20, 20614–20641. [Google Scholar] [CrossRef]
- Huang, M. T.; Ho, C. T.; Wang, Z. Y.; Ferraro, T.; Lou, Y. R.; Stauber, K.; Ma, W.; Georgiadis, C.; Laskin, J. D.; Conney, A. H. Inhibition of skin tumorigenesis by rosemary and its constituents carnosol and ursolic acid. Cancer Res 1994, 54, 701–708. [Google Scholar]
- Liu, W.; Tan, X.; Shu, L.; Sun, H.; Song, J.; Jin, P.; Yu, S.; Sun, M.; Jia, X. Ursolic acid inhibits cigarette smoke extract-induced human bronchial epithelial cell injury and prevents development of lung cancer. Molecules 2012, 17, 9104–9115. [Google Scholar] [CrossRef] [PubMed]
- Gayathri, R.; Priya, D. K.; Gunassekaran, G. R.; Sakthisekaran, D. Ursolic acid attenuates oxidative stress-mediated hepatocellular carcinoma induction by diethylnitrosamine in male Wistar rats. Asian Pac J Cancer Prev 2009, 10, 933–938. [Google Scholar] [PubMed]
- Hsu, H. Y.; Yang, J. J.; Lin, C. C. Effects of oleanolic acid and ursolic acid on inhibiting tumor growth and enhancing the recovery of hematopoietic system postirradiation in mice. Cancer Lett 1997, 111, 7–13. [Google Scholar] [CrossRef] [PubMed]
- Ohigashi, H.; Takamura, H.; Koshimizu, K.; Tokuda, H.; Ito, Y. Search for possible antitumor promoters by inhibition of 12-O-tetradecanoylphorbol-13-acetate-induced Epstein-Barr virus activation; ursolic acid and oleanolic acid from an anti-inflammatory Chinese medicinal plant, Glechoma hederaceae L. Cancer Lett 1986, 30, 143–151. [Google Scholar] [CrossRef] [PubMed]
- Ghantous, A.; Sinjab, A.; Herceg, Z.; Darwiche, N. Parthenolide: from plant shoots to cancer roots. Drug Discov Today 2013, 18, 894–905. [Google Scholar] [CrossRef] [PubMed]
- Hehner, S. P.; Hofmann, T. G.; Dröge, W.; Schmitz, M. L. The antiinflammatory sesquiterpene lactone parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 1999, 163, 5617–5623. [Google Scholar] [CrossRef] [PubMed]
- D’Anneo, A.; Carlisi, D.; Lauricella, M.; Puleio, R.; Martinez, R.; Di Bella, S.; Di Marco, P.; Emanuele, S.; Di Fiore, R.; Guercio, A.; et al. Parthenolide generates reactive oxygen species and autophagy in MDA-MB231 cells. A soluble parthenolide analogue inhibits tumour growth and metastasis in a xenograft model of breast cancer. Cell Death Dis 2013, 4, e891. [Google Scholar] [CrossRef]
- Flores-Lopez, G.; Moreno-Lorenzana, D.; Ayala-Sanchez, M.; Aviles-Vazquez, S.; Torres-Martinez, H.; Crooks, P. A.; Guzman, M. L.; Mayani, H.; Chávez-González, A. Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species. J Cell Mol Med 2018, 22, 4899–4912. [Google Scholar] [CrossRef]
- Li, X.; Huang, R.; Li, M.; Zhu, Z.; Chen, Z.; Cui, L.; Luo, H.; Luo, L. Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptor. Cancer Cell Int 2020, 20, 561. [Google Scholar] [CrossRef]
- Mathema, V. B.; Koh, Y. S.; Thakuri, B. C.; Sillanpää, M. Parthenolide, a sesquiterpene lactone, expresses multiple anti-cancer and anti-inflammatory activities. Inflammation 2012, 35, 560–565. [Google Scholar] [CrossRef]
- Pettit, R. E. Organic matter, humus, humate, humic acid, fulvic acid and humin: their importance in soil fertility and plant health. CTI Research 2004, 10, 1–7. [Google Scholar]
- Ghosal, S. Chemistry of shilajit, an immunomodulatory Ayurvedic rasayan. Pure and Applied Chemistry 1990, 62, 1285–1288. [Google Scholar] [CrossRef]
- Winkler, J.; Ghosh, S. Therapeutic Potential of fulvic acid in chronic inflammatory diseases and diabetes. J Diabetes Res 2018, 2018, 5391014. [Google Scholar] [CrossRef] [PubMed]
- Jayasooriya, R. G. P. T.; Dilshara, M. G.; Kang, C. H.; Lee, S.; Choi, Y. H.; Jeong, Y. K.; Kim, G. Y. Fulvic acid promotes extracellular anti-cancer mediators from RAW 264.7 cells, causing to cancer cell death in vitro. Int Immunopharmacol 2016, 36, 241–248. [Google Scholar] [CrossRef] [PubMed]
- Salehi, M.; Piri, H.; Farasat, A.; Pakbin, B.; Gheibi, N. Activation of apoptosis and G0/G1 cell cycle arrest along with inhibition of melanogenesis by humic acid and fulvic acid. Iran J Basic Med Sci 2022, 25, 489–496. [Google Scholar] [CrossRef] [PubMed]
- Zhang, X. F.; Yang, G.; Dong, Y.; Zhao, Y. Q.; Sun, X. R.; Chen, L.; Chen, H. B. Studies on the binding of fulvic acid with transferrin by spectroscopic analysis. Spectrochim Acta A Mol Biomol Spectrosc 2015, 137, 1280–1285. [Google Scholar] [CrossRef] [PubMed]
- Nicolaou, K. C.; Yang, Z.; Liu, J. J.; Ueno, H.; Nantermet, P. G.; Guy, R. K.; Claiborne, C. F.; Renaud, J.; Couladouros, E. A.; Paulvannan, K. Total synthesis of taxol. Nature 1994, 367, 630–634. [Google Scholar] [CrossRef] [PubMed]
- Zhu, L.; Chen, L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett 2019, 24, 40. [Google Scholar] [CrossRef]
- Cragg, G. M.; Newman, D. J. Plants as a source of anti-cancer agents. J Ethnopharmacol 2005, 100, 72–79. [Google Scholar] [CrossRef] [PubMed]
- Bian, F.; Su, J.; Liu, W.; Li, S. Dormancy release and germination of Taxus yunnanensis seeds during wet sand storage. Sci Rep 2018, 8, 3205. [Google Scholar] [CrossRef]
- Yu, C.; Luo, X.; Zhan, X.; Hao, J.; Zhang, L.; L Song, Y. B.; Shen, C.; Dong, M. Comparative metabolomics reveals the metabolic variations between two endangered Taxus species (T. fuana and T. yunnanensis) in the Himalayas. BMC Plant Biol 2018, 18, 197. [Google Scholar] [CrossRef] [PubMed]
- Yan, C.; Yin, Y.; Zhang, D.; Yang, W.; Yu, R. Structural characterization and in vitro antitumor activity of a novel polysaccharide from Taxus yunnanensis. Carbohydr Polym 2013, 96, 389–395. [Google Scholar] [CrossRef] [PubMed]
- Hafezi, K.; Hemmati, A. A.; Abbaszadeh, H.; Valizadeh, A.; Makvandi, M. Anticancer activity and molecular mechanisms of α-conidendrin, a polyphenolic compound present in Taxus yunnanensis, on human breast cancer cell lines. Phytother Res 2020, 34, 1397–1408. [Google Scholar] [CrossRef] [PubMed]
- Jin, J.; Cai, D.; Bi, H.; Zhong, G.; Zeng, H.; Gu, L.; Huang, Z.; Huang, M. Comparative pharmacokinetics of paclitaxel after oral administration of Taxus yunnanensis extract and pure paclitaxel to rats. Fitoterapia 2013, 90, 1–9. [Google Scholar] [CrossRef]
- Akao, Y.; Terazawa, R.; Sugito, N.; Heishima, K.; Morikawa, K.; Ito, Y.; Narui, R.; Hamaguchi, R.; Nobukawa, T. Understanding of cell death induced by the constituents of Taxus yunnanensis wood. Sci Rep 2022, 12, 6282. [Google Scholar] [CrossRef]
- Emran, T. B.; Islam, F.; Mitra, S.; Paul, S.; Nath, N.; Khan, Z.; Das, R.; Chandran, D.; Sharma, R.; Lima, C. M. G.; et al. Pectin: A bioactive food polysaccharide with cancer preventive potential. Molecules 2022, 27. [Google Scholar] [CrossRef]
- Leclere, L.; Cutsem, P. V.; Michiels, C. Anti-cancer activities of pH- or heat-modified pectin. Front Pharmacol 2013, 4, 128. [Google Scholar] [CrossRef]
- Olano-Martin, E.; Rimbach, G. H.; Gibson, G. R.; Rastall, R. A. Pectin and pectic-oligosaccharides induce apoptosis in in vitro human colonic adenocarcinoma cells. Anticancer Res 2003, 23, 341–346. [Google Scholar]
- Delphi, L.; Sepehri, H. Apple pectin: A natural source for cancer suppression in 4T1 breast cancer cells in vitro and express p53 in mouse bearing 4T1 cancer tumors, in vivo. Biomed Pharmacother 2016, 84, 637–644. [Google Scholar] [CrossRef]
- Keizman, D.; Frenkel, M.; Peer, A.; Kushnir, I.; Rosenbaum, E.; Sarid, D.; Leibovitch, I.; Mano, R.; Yossepowitch, O.; Margel, D.; et al. Modified citrus pectin treatment in non-metastatic biochemically relapsed prostate cancer: Results of a prospective phase II study. Nutrients 2021, 13. [Google Scholar] [CrossRef] [PubMed]
- Grimes, D. R.; O’Riordan, E. Starving cancer and other dangerous dietary misconceptions. Lancet Oncol 2023, 24, 1177–1178. [Google Scholar] [CrossRef] [PubMed]
- Zick, S. M.; Snyder, D.; Abrams, D. I. Pros and cons of dietary strategies popular among cancer patients. Oncology (Williston Park) 2018, 32, 542–547. [Google Scholar] [PubMed]

| No. of patients | 49 |
| Age (range), years | 62.2 (39–86) |
| Sex Men Women |
22 27 |
| Progression of cancer Metastasis Recurrence after surgery |
31 18 |
| Diagnosis of cancer Non-small cell lung cancer Breast cancer Hepatic cancer Gastric cancer Colon cancer Small cell lung cancer Pancreatic cancer Prostate cancer Oropharyngeal cancer Thymic cancer Kidney cancer Duodenal papillary cancer Uterine cancer Cancer of unknown primary |
18 9 4 3 3 2 2 2 1 1 1 1 1 1 |
| Natural products Triterpenoid Parthenolide Fulvic acid Taxus yunnanensis Apple pectin |
48 19 11 5 2 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).